Nasal spray preparation for resisting respiratory virus infection

A virus infection and anti-respiratory technology, which is applied in the direction of antiviral agents, respiratory diseases, aerosol delivery, etc., can solve the problems of clinical application limitations, achieve enhanced clinical indications, enhance the scope of anti-virus, and be convenient and simple to use Effect

Pending Publication Date: 2020-08-14
XIAMEN NUOKANGDE BIOLOGICAL TECH CO LTD +1
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to the results of pharmacokinetic studies in humans and mice, rACE2 has a high clearance rate and a half-life of only a few hours, which limits its clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasal spray preparation for resisting respiratory virus infection
  • Nasal spray preparation for resisting respiratory virus infection
  • Nasal spray preparation for resisting respiratory virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Preparation of liposome-ACE2

[0029] According to the liposome mixture (lipid mixture) component molar ratio is DPPC:Chol:DSPE-PEG2K:DSPE-PEG-MAL is 60:40:4:1, each component of liposome is weighed successively, and the total molar number is about 26 μmol, then add 5mL CHCl 3 dissolved, and the chloroform (CHCl 3 ), and then use a vacuum pump for 1 hour to completely remove CHCl 3 , then add 10mL of PBS solution, ultrasonic in water bath for about half an hour, then dialyze, extrude to form liposome (liposome), the ACE2 extracellular segment recombinant protein (its amino acid sequence is as SEQ ID NO) after dithiothreitol DTT treatment NO: 1) was added to the above liposome suspension, reacted at room temperature for 24 hours and dialyzed to obtain ACE2-modified liposomes (liposome-ACE2), and BCA was used to measure the concentration of recombinant protein in the extracellular segment of ACE2.

[0030] Liposome-loaded angiotensin-converting enzyme 2 (ACE2...

Embodiment 2

[0032] Preparation of nasal spray preparation for embodiment 2 anti-respiratory virus infection

[0033] 0.5 mg / mL of ACE2 extracellular segment recombinant protein (liposome-ACE2) loaded on liposomes prepared in Example 1 above, 5 mg / mL of N-acetylneuraminic acid (Neu5Ac), 0.6 mg / mL of fucoidan and Chitosan 0.4 mg / mL is dissolved in physiological saline, and the pH is adjusted to 6.5-7.0 to prepare a nasal cavity spray preparation for resisting respiratory virus infection.

Embodiment 3

[0034] Example 3 Cell Fusion Inhibition Experiment

[0035] 293T cells transfected with SARS CoV and 2019-nCoV S glycoprotein genes were pre-incubated with the anti-respiratory virus infection nasal spray prepared in Example 2 for 15 minutes at room temperature, and then mixed with 293T cells transfected with ACE2 gene in equal proportions , and incubated at 37°C for 4h. After the incubation, the cells were lysed, the β-gal activity was measured, and the inhibitory effect of nasal spray on cell fusion was calculated. In the control group, PBS was used instead of nasal spray.

[0036] The result is as Figure 4 and Figure 5 As shown, the results show that the anti-respiratory virus infection nasal spray preparation prepared by the embodiment of the present invention has a good inhibitory effect on the cell fusion mediated by ACE2 and coronavirus S protein, and compared with the PBS control group, it has the highest inhibitory rate to SARS CoV It is about 96%, and its highest i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to a nasal spray preparation for resisting respiratory virus infection. The preparation comprises liposome-loaded angiotensin converting enzyme 2 (ACE2) recombinant protein, sialic acid, natural polysaccharide and normal saline. The nasal spray preparation is mainly prepared from the liposome-loaded ACE2 extracellular domain recombinant protein, can competitively inhibit thecombination of viruses and host cells, prevents and treats respiratory tract infection caused by various viruses, and enhances the antiviral range and clinical indications of the nasal spray preparation for resisting respiratory tract virus infection. In addition, the nasal spray preparation can be used for directly spraying medicines to virus propagation parts, and is convenient and simple to use.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a nasal cavity spray preparation for resisting respiratory virus infection. Background technique [0002] Respiratory tract infectious diseases refer to infectious diseases caused by the invasion of pathogens such as viruses, bacteria, mycoplasma and chlamydia through respiratory infection. Common winter and spring respiratory infectious diseases include influenza caused by influenza virus, influenza caused by coronavirus, adenovirus Common cold, acute pneumonia, etc. caused by viruses, etc. [0003] The new coronavirus 2019-nCov is a coronavirus that has not been found in humans before. It invades the lungs through the respiratory tract and causes severe pneumonia as the main mode of pathogenicity. The new coronavirus 2019-nCov is evolutionarily similar to the SARS virus, and belongs to the genus of coronavirus beta, and its gene sequence similarity with the SARS coronavirus is 82%...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K9/12A61P11/00A61P31/16A61P31/14A61K31/351
CPCA61K38/16A61K31/351A61K9/0043A61K9/12A61K47/36A61P11/00A61P31/16A61P31/14A61K2300/00
Inventor 李柱李勤斌田云鹏赵绍军
Owner XIAMEN NUOKANGDE BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap